{
  "url": "https://www.morningstar.com/news/pr-newswire/20250815la52921/ryght-ai-partners-with-global-cro-biorasi-to-deliver-ai-powered-feasibility-solutions-to-biotech-and-biopharma-sponsors",
  "authorsByline": "",
  "articleId": "df35b0d9e1764f049c7edd172c276514",
  "source": {
    "domain": "morningstar.com",
    "location": {
      "country": "us",
      "state": "IL",
      "county": "Cook County",
      "city": "Chicago",
      "coordinates": {
        "lat": 41.8755616,
        "lon": -87.6244212
      }
    }
  },
  "imageUrl": "https://images.contentstack.io/v3/assets/blt4eb669caa7dc65b2/blta7dd42ebdd7b93b8/61899b34a3c7df383578294c/morningstar-og.png",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-15T16:35:00-05:00",
  "addDate": "2025-08-15T21:54:04.112047+00:00",
  "refreshDate": "2025-08-15T21:54:04.112049+00:00",
  "score": 1.0,
  "title": "Ryght AI Partners with Global CRO Biorasi to Deliver AI-Powered Feasibility Solutions to Biotech and Biopharma Sponsors",
  "description": "",
  "content": "Advanced AI Platform Enables More Accurate Site Selection and Faster Study Startup Across Key Therapeutic Areas\n\nPartnership brings real-time site identification, feasibility, activation and automated trial optimization to Biorasi's sponsor clients, reducing trial delays and improving cost effectiveness\n\nLAGUNA BEACH, Calif., Aug. 15, 2025 /PRNewswire/ -- Ryght AI, the clinical trials AI technology company transforming site activation and optimization through AI digital twins of every research site in the world, today announced a strategic partnership with Biorasi, a leading global clinical research organization (CRO) specializing in dermatology, oncology, neurology, and nephrology studies. This collaboration immediately enhances Biorasi's service offering to biotech and biopharma sponsors with Ryght's advanced AI-driven site selection and feasibility platform.\n\nThe partnership addresses critical industry challenges that cost sponsors millions annually: inaccurate site selection, prolonged feasibility timelines, unpredictable enrollment forecasting and suboptimal site performance. By integrating Ryght AI's platform into Biorasi's operations, sponsors gain access to granular, real-time insights on site performance and recruitment capacity \u2013 transforming site selection, feasibility and trial performance from guesswork into data-driven decision making.\n\n\"Traditional feasibility models can be limited by static, self-reported data,\" said Chris O'Brien, CEO at Biorasi. \"Ryght AI's platform revolutionizes these models. With continuously updated digital twins of clinical sites and AI-powered feasibility automation, Biorasi can now provide sponsors with recruitment forecasts grounded in real-world, site-specific data.\"\n\u2022 Automated Feasibility Workflows: Pre-populated feasibility questionnaire webforms with validated data compress traditional feasibility timelines from several months to less than 3 weeks\n\u2022 Agentic AI Copilots: Rapid protocol parsing and automated generation of feasibility questionnaires, IRB packets, and investigator outreach materials\n\n\"We're transforming clinical trial feasibility into reliable and vital study data,\" said Simon Arkell, CEO at Ryght AI. \"Biorasi's focus on pragmatic AI solutions makes them a perfect partner for optimizing clinical site selection.\"\n\nBiorasi's sponsor clients can expect significant improvements in study startup and execution across multiple categories, including:\n\u2022 Enhanced Accuracy: More precise enrollment forecasting and budget modeling reduce financial risk\n\u2022 Cost Optimization: Decreased risk of mid-trial delays and cost overruns through better upfront planning\n\nThe partnership represents Ryght AI's continued expansion of its AI-powered clinical research platform, which maintains SOC Type 2 compliance while fostering seamless, real-time communication between sponsors, CROs, and research sites.\n\nRyght AI is transforming clinical research with a cutting-edge platform that includes an AI digital twin of every research site across the globe. This innovative approach empowers sponsors and CROs to significantly accelerate clinical trial study startup through faster site selection and streamlined feasibility workflows, all powered by advanced generative and agentic AI. Furthermore, Ryght's SOC Type 2-compliant platform enhances efficiency by fostering seamless, real-time communication between sponsors, CROs, and research sites.\n\nFor more information, please visitwww.ryght.ai. To discuss AI-powered clinical trial solutions or network membership for your site, CRO or biopharma company, please email sales@ryght.ai.\n\nBiorasi is a global clinical research organization (CRO) that delivers speed-to-market strategies for small to midsized biotech and biopharma sponsors. With over two decades of expertise in running clinical trials across dermatology, oncology, neurology, nephrology, and other key therapeutic areas, Biorasi leverages reliable, flexible, and accessible solutions necessary to succeed in today's dynamic and evolving clinical trials industry. Contact Biorasi at info@biorasi.com / (786) 388-0700.",
  "medium": "Article",
  "links": [
    "https://c212.net/c/link/?t=0&l=en&o=4489747-1&h=3983848208&u=https%3A%2F%2Fbiorasi.com%2F&a=Biorasi",
    "https://c212.net/c/link/?t=0&l=en&o=4489747-1&h=3429500866&u=http%3A%2F%2Fwww.ryght.ai%2F&a=www.ryght.ai",
    "https://mma.prnewswire.com/media/2751739/Ryght_AI_and_global_CRO_Biorasi_collab.html",
    "https://www.prnewswire.com/news-releases/ryght-ai-partners-with-global-cro-biorasi-to-deliver-ai-powered-feasibility-solutions-to-biotech-and-biopharma-sponsors-302531395.html",
    "https://mma.prnewswire.com/media/2263434/Ryght_Logo_4x_Logo.html",
    "https://c212.net/c/link/?t=0&l=en&o=4489747-1&h=2460750424&u=http%3A%2F%2Fwww.ryght.ai%2F&a=+"
  ],
  "labels": [
    {
      "name": "Press Release"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "clinical trial feasibility",
      "weight": 0.112085
    },
    {
      "name": "clinical site selection",
      "weight": 0.10949652
    },
    {
      "name": "clinical sites",
      "weight": 0.10699999
    },
    {
      "name": "research sites",
      "weight": 0.09928991
    },
    {
      "name": "clinical trial study startup",
      "weight": 0.0963467
    },
    {
      "name": "Ryght AI",
      "weight": 0.09585079
    },
    {
      "name": "site selection",
      "weight": 0.09579687
    },
    {
      "name": "clinical trials",
      "weight": 0.09571863
    },
    {
      "name": "Advanced AI Platform",
      "weight": 0.09228737
    },
    {
      "name": "clinical research",
      "weight": 0.0920594
    }
  ],
  "topics": [
    {
      "name": "Biotech"
    },
    {
      "name": "AI"
    }
  ],
  "categories": [
    {
      "name": "Tech"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Company News",
      "score": 0.93115234375
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.8076171875
    },
    {
      "name": "/Health/Health Foundations & Medical Research",
      "score": 0.67626953125
    },
    {
      "name": "/Science/Computer Science/Machine Learning & Artificial Intelligence",
      "score": 0.6689453125
    },
    {
      "name": "/Computers & Electronics/Software/Business & Productivity Software",
      "score": 0.611328125
    },
    {
      "name": "/News/Technology News",
      "score": 0.5751953125
    },
    {
      "name": "/News/Health News",
      "score": 0.3662109375
    }
  ],
  "sentiment": {
    "positive": 0.73841536,
    "negative": 0.026923057,
    "neutral": 0.23466153
  },
  "summary": "Ryght AI, a clinical trials AI technology company, has partnered with Biorasi, a global CRO specializing in dermatology, oncology, neurology, and nephrology studies, to deliver AI-Powered Feasibility Solutions to Biotech and Biopharma Sponsors. The partnership addresses key industry challenges that cost sponsors millions annually: inaccurate site selection, prolonged feasibility timelines, unpredictable enrollment forecasting, and suboptimal site performance. The collaboration allows sponsors to access real-time site identification, feasibility, activation, and trial optimization, reducing trial delays and cost effectiveness. Ryght's advanced AI-driven site selection and feasibility platform enables more accurate site Selection and faster study startup across key therapeutic areas. The company's AI-powered clinical research platform includes an AI digital twin of every research site across the globe.",
  "shortSummary": "Ryght AI and global CRO Biorasi provide AI-powered feasibility solutions for biotech and biopharma sponsors, enhancing clinical trial startup and efficiency.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": true,
  "reprintGroupId": "76967b2f9d08422ab444295c4a81f689",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://c212.net/c/link/?t=0&l=en&o=4489747-1&h=2460750424&u=http%3A%2F%2Fwww.ryght.ai%2F&a=+",
      "text": "Supercharge site selection and feasibility with AI Site Twins of every research site on the planet\nRyght AI's generative AI platform enables sponsors and CROs to quickly find, select, and activate the best sites for their study protocols \u2014 and continuously optimize site performance after activation.\nSupercharge site selection and feasibility with AI digital twins of every research site on the planet\nRyght AI's generative AI platform enables sponsors and CROs to quickly find, select, and activate the best sites for their study protocols \u2014 and continuously optimize site performance after activation.\nTraditional site selection and feasibility methods are outdated, inefficient and expensive\nSponsors and CROs are still relying on outdated spreadsheets of disparate data to evaluate sites, and assessing feasibility is plagued by guesswork and slow response times.\nIdentify the best sites, activate faster and start enrollment sooner\nRyght AI rapidly analyzes your protocol and then instantly connects you with high-potential research sites\u2014anywhere in the world.\nOur technology streamlines site selection, accelerates activation, gets your studies enrolling patients sooner than traditional approaches, then optimizes site performance for the duration of the trial.\nIdentify the best sites, activate faster and start enrollment sooner\nRyght AI rapidly analyzes your protocol and then instantly connects you with high-potential research sites\u2014anywhere in the world.\nOur technology streamlines site selection, accelerates activation, gets your studies enrolling patients sooner than traditional approaches, then optimizes site performance for the duration of the trial.\nWhat is an AI Site Twin?\nRyght's AI Site Twins are digital replicas of every clinical research site in the world. Built on the established concept of digital twins, these virtual representations capture a site's unique operational characteristics, historical trial performance, and patient populations.\nThis powerful AI-powered platform provides sponsors and CROs with the predictive capabilities they need to enhance site selection, feasibility, and study optimization throughout the life of the trial.\nIngest + Analyze\nLeverage advanced AI and machine learning algorithms to analyze complex datasets and identify patterns in seconds.\nSimulate + Forecast\nRun potential scenarios to predict enrollment performance and anticipate potential issues or opportunities\nDynamic + Interactive\nEvery twin is constantly updated by AI retriever agents with real-time data from public and other sources, reflecting changes in the physical world.\nOptimize + Adapt\nAdjust protocol parameters in real-time based on emerging data, leading to more efficient and successful trials.\nA complete, dynamic data-derived replica of every clinical research site on the planet\nA complete, dynamic data-derived replica of every clinical research site on the planet\nExplore the Ryght AI platform\nUpload your protocol, and Ryght will instantly analyze our network of AI Site Twins to identify the best-fit clinical research sites for your study.\nAutomatically send qualified sites pre-populated feasibility questionnaires powered by data from our AI Site Twin network. All sites need to do is review and approve - saving weeks of wait time.\nAvailable on the Microsoft Azure Marketplace\nRyght is available on Microsoft Azure Marketplace, making it easy for sponsors and CROs to use existing cloud commitments, simplify billing, and increase cost efficiency.\nDiscover the difference AI-powered site selection and feasibility can make.\nSkeptical? We get it. AI-powered site selection in minutes does sound a little too good to be true. That's why we\u2019re ready to demonstrate Ryght\u2019s capabilities for you in real time.\nJust give us twenty minutes and an old protocol, and we'll show you how quickly Ryght finds the best-fit sites for your trial before you finish your coffee.\nTrusted by top healthcare and research companies worldwide\n\"By streamlining study selection, feasibility, and patient referrals, the Ryght Research Network will allow us to focus more on advancing patient care and less on administrative burden while running the trials that are most likely to succeed.\"\n\"Ryght Al's unique and powerful platform streamlines clinical trials from site selection to activation nd enrollment, ultimately speeding up time to market for our biopharma clients.\"\n\"At the University of Adelaide, we are committed to advancing world-class research that addresses many of the challenges faced by society. By working together, we can leverage our collective expertise to develop innovative, responsible and tested solutions for better public health and other critical issues and bring Australia's Al capabilities up to world-class standards where they belong.\"\nStay Connected\nSubscribe to be the first to know about product updates, news and announcements."
    },
    {
      "url": "https://c212.net/c/link/?t=0&l=en&o=4489747-1&h=3983848208&u=https%3A%2F%2Fbiorasi.com%2F&a=Biorasi",
      "text": "Biorasi: Faster clinical trials\nBiorasi is a global, award-winning and full-service contract research organization (CRO) that delivers the speed and agility that today\u2019s small and midsized pharmaceutical and device companies desperately need. We accelerate your clinical trials to rapid completion with our unconventional approach to clinical research.\nBiorasi is faster than other CROs throughout the entire life cycle of the trial, from initial engagement to study closeout.\nEnable FPI faster.\nExperience the joy of streamlined start-up.\nGo-live in record time.\nExperience the science behind Biorasi data.\nGet in step with the patient journey.\nExperience our recruitment solutions.\nHave your keys handy.\nSee our strategies to accelerate data cleaning and get you ready for database lock.\nKnow sooner.\nExperience rapid, reliable results.\nBiorasi is setting the new benchmark in speed and raising the bar in CRO quality.\nDiscover More about how the fastest CRO in the industry still delivers premium performance.\nRare and Urgent Disease\nReal solutions\nRare Disease\nReal solutions\nSpeed and agility are at the core of a successful rare disease clinical trial. Biorasi excels in overcoming common challenges faced during these studies, leveraging industry expertise, cutting-edge technology, and our deep commitment to rare disease clinical research.\nPatient Recruitment\nRapid enrollment\nPatient Recruitment\nRapid enrollment\nThe faster you recruit, the faster your trials finish. Biorasi enrolls your patients eight times quicker than other CROs by optimizing patient-centric strategies, deploying local and global clinical trial recruitment solutions, and customizing individual enrollment plans for rare disease.\nDECENTRALIZED TRIALS\nFlexible tech\nDECENTRALIZED TRIALS\nFlexible tech\nBiorasi\u2019s decentralized solutions empower you to adapt seamlessly to everyday challenges and unforeseen obstacles. Our complete virtual clinical trial conduct at remote or inaccessible locations, such as during lockdowns, keeps your pivotal studies moving forward. Take the risk out of your clinical studies and stay agile with our remote monitoring and remote patient solutions.\nThe Latest Insights From Biorasi\nArticle\nOff-Script FDA: How Smart Teams Pivot, Escalate, and Progress\nArticle\nThe Rescue Option: Course Correcting Struggling Clinical Trials\nDaring To Learn From Failure: Insights On The Future Of Stem Cell Therapy\nArticle"
    },
    {
      "url": "https://www.prnewswire.com/news-releases/ryght-ai-partners-with-global-cro-biorasi-to-deliver-ai-powered-feasibility-solutions-to-biotech-and-biopharma-sponsors-302531395.html",
      "text": "Advanced AI Platform Enables More Accurate Site Selection and Faster Study Startup Across Key Therapeutic Areas\nPartnership brings real-time site identification, feasibility, activation and automated trial optimization to Biorasi's sponsor clients, reducing trial delays and improving cost effectiveness\nLAGUNA BEACH, Calif., Aug. 15, 2025 /PRNewswire/ -- Ryght AI, the clinical trials AI technology company transforming site activation and optimization through AI digital twins of every research site in the world, today announced a strategic partnership with Biorasi, a leading global clinical research organization (CRO) specializing in dermatology, oncology, neurology, and nephrology studies. This collaboration immediately enhances Biorasi's service offering to biotech and biopharma sponsors with Ryght's advanced AI-driven site selection and feasibility platform.\nRevolutionizing Feasibility with Dynamic AI Digital Twins of Research Sites\nThe partnership addresses critical industry challenges that cost sponsors millions annually: inaccurate site selection, prolonged feasibility timelines, unpredictable enrollment forecasting and suboptimal site performance. By integrating Ryght AI's platform into Biorasi's operations, sponsors gain access to granular, real-time insights on site performance and recruitment capacity \u2013 transforming site selection, feasibility and trial performance from guesswork into data-driven decision making.\n\"Traditional feasibility models can be limited by static, self-reported data,\" said Chris O'Brien, CEO at Biorasi. \"Ryght AI's platform revolutionizes these models. With continuously updated digital twins of clinical sites and AI-powered feasibility automation, Biorasi can now provide sponsors with recruitment forecasts grounded in real-world, site-specific data.\"\nRyght AI's platform addresses these limitations through:\n- Dynamic AI Digital Twins: Continuously updated profiles of global clinical sites featuring real-time recruitment capacity, historical trial performance, and operational readiness metrics\n- Automated Feasibility Workflows: Pre-populated feasibility questionnaire webforms with validated data compress traditional feasibility timelines from several months to less than 3 weeks\n- Agentic AI Copilots: Rapid protocol parsing and automated generation of feasibility questionnaires, IRB packets, and investigator outreach materials\nMeasurable Impact for Sponsors\n\"We're transforming clinical trial feasibility into reliable and vital study data,\" said Simon Arkell, CEO at Ryght AI. \"Biorasi's focus on pragmatic AI solutions makes them a perfect partner for optimizing clinical site selection.\"\nBiorasi's sponsor clients can expect significant improvements in study startup and execution across multiple categories, including:\n- Enhanced Accuracy: More precise enrollment forecasting and budget modeling reduce financial risk\n- Reduced Delays: Faster site startup through intelligent automation and comprehensive site prequalification\n- Cost Optimization: Decreased risk of mid-trial delays and cost overruns through better upfront planning\n- Improved Efficiency: Streamlined site engagement reaching only high-fit, high-capacity research partners\nThe partnership represents Ryght AI's continued expansion of its AI-powered clinical research platform, which maintains SOC Type 2 compliance while fostering seamless, real-time communication between sponsors, CROs, and research sites.\nAbout Ryght:\nRyght AI is transforming clinical research with a cutting-edge platform that includes an AI digital twin of every research site across the globe. This innovative approach empowers sponsors and CROs to significantly accelerate clinical trial study startup through faster site selection and streamlined feasibility workflows, all powered by advanced generative and agentic AI. Furthermore, Ryght's SOC Type 2-compliant platform enhances efficiency by fostering seamless, real-time communication between sponsors, CROs, and research sites.\nFor more information, please visit www.ryght.ai. To discuss AI-powered clinical trial solutions or network membership for your site, CRO or biopharma company, please email [email protected].\nAbout Biorasi\nBiorasi is a global clinical research organization (CRO) that delivers speed-to-market strategies for small to midsized biotech and biopharma sponsors. With over two decades of expertise in running clinical trials across dermatology, oncology, neurology, nephrology, and other key therapeutic areas, Biorasi leverages reliable, flexible, and accessible solutions necessary to succeed in today's dynamic and evolving clinical trials industry. Contact Biorasi at [email protected] / (786) 388-0700.\nMedia Contact:\nAriel Paradis\n[email protected]\nSOURCE Ryght\nWANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?\nNewsrooms &\nInfluencers\nDigital Media\nOutlets\nJournalists\nOpted In\nShare this article"
    },
    {
      "url": "https://c212.net/c/link/?t=0&l=en&o=4489747-1&h=3429500866&u=http%3A%2F%2Fwww.ryght.ai%2F&a=www.ryght.ai",
      "text": "Supercharge site selection and feasibility with AI Site Twins of every research site on the planet\nRyght AI's generative AI platform enables sponsors and CROs to quickly find, select, and activate the best sites for their study protocols \u2014 and continuously optimize site performance after activation.\nSupercharge site selection and feasibility with AI digital twins of every research site on the planet\nRyght AI's generative AI platform enables sponsors and CROs to quickly find, select, and activate the best sites for their study protocols \u2014 and continuously optimize site performance after activation.\nTraditional site selection and feasibility methods are outdated, inefficient and expensive\nSponsors and CROs are still relying on outdated spreadsheets of disparate data to evaluate sites, and assessing feasibility is plagued by guesswork and slow response times.\nIdentify the best sites, activate faster and start enrollment sooner\nRyght AI rapidly analyzes your protocol and then instantly connects you with high-potential research sites\u2014anywhere in the world.\nOur technology streamlines site selection, accelerates activation, gets your studies enrolling patients sooner than traditional approaches, then optimizes site performance for the duration of the trial.\nIdentify the best sites, activate faster and start enrollment sooner\nRyght AI rapidly analyzes your protocol and then instantly connects you with high-potential research sites\u2014anywhere in the world.\nOur technology streamlines site selection, accelerates activation, gets your studies enrolling patients sooner than traditional approaches, then optimizes site performance for the duration of the trial.\nWhat is an AI Site Twin?\nRyght's AI Site Twins are digital replicas of every clinical research site in the world. Built on the established concept of digital twins, these virtual representations capture a site's unique operational characteristics, historical trial performance, and patient populations.\nThis powerful AI-powered platform provides sponsors and CROs with the predictive capabilities they need to enhance site selection, feasibility, and study optimization throughout the life of the trial.\nIngest + Analyze\nLeverage advanced AI and machine learning algorithms to analyze complex datasets and identify patterns in seconds.\nSimulate + Forecast\nRun potential scenarios to predict enrollment performance and anticipate potential issues or opportunities\nDynamic + Interactive\nEvery twin is constantly updated by AI retriever agents with real-time data from public and other sources, reflecting changes in the physical world.\nOptimize + Adapt\nAdjust protocol parameters in real-time based on emerging data, leading to more efficient and successful trials.\nA complete, dynamic data-derived replica of every clinical research site on the planet\nA complete, dynamic data-derived replica of every clinical research site on the planet\nExplore the Ryght AI platform\nUpload your protocol, and Ryght will instantly analyze our network of AI Site Twins to identify the best-fit clinical research sites for your study.\nAutomatically send qualified sites pre-populated feasibility questionnaires powered by data from our AI Site Twin network. All sites need to do is review and approve - saving weeks of wait time.\nAvailable on the Microsoft Azure Marketplace\nRyght is available on Microsoft Azure Marketplace, making it easy for sponsors and CROs to use existing cloud commitments, simplify billing, and increase cost efficiency.\nDiscover the difference AI-powered site selection and feasibility can make.\nSkeptical? We get it. AI-powered site selection in minutes does sound a little too good to be true. That's why we\u2019re ready to demonstrate Ryght\u2019s capabilities for you in real time.\nJust give us twenty minutes and an old protocol, and we'll show you how quickly Ryght finds the best-fit sites for your trial before you finish your coffee.\nTrusted by top healthcare and research companies worldwide\n\"By streamlining study selection, feasibility, and patient referrals, the Ryght Research Network will allow us to focus more on advancing patient care and less on administrative burden while running the trials that are most likely to succeed.\"\n\"Ryght Al's unique and powerful platform streamlines clinical trials from site selection to activation nd enrollment, ultimately speeding up time to market for our biopharma clients.\"\n\"At the University of Adelaide, we are committed to advancing world-class research that addresses many of the challenges faced by society. By working together, we can leverage our collective expertise to develop innovative, responsible and tested solutions for better public health and other critical issues and bring Australia's Al capabilities up to world-class standards where they belong.\"\nStay Connected\nSubscribe to be the first to know about product updates, news and announcements."
    }
  ],
  "argos_summary": "Ryght AI has partnered with CRO Biorasi to integrate its AI\u2011powered platform of digital twins for clinical research sites, offering sponsors real\u2011time, data\u2011driven site selection, feasibility, and enrollment forecasting. The collaboration promises to cut feasibility timelines from months to under three weeks, improve enrollment accuracy, reduce cost overruns, and accelerate study startup across dermatology, oncology, neurology, and nephrology. By automating feasibility workflows and providing continuously updated site profiles, the partnership aims to transform trial planning from guesswork into precise, AI\u2011guided decision making.",
  "argos_id": "PK21OFU7O"
}